July 2011 Newsletter

July 25, 2011:

New Ophthalmic Diagnostic Technologies are Advancing Medical Care and Fueling Markets

New ophthalmic diagnostic technologies are advancing care, particularly when they work in synergy with new treatment paradigms.

July 25, 2011:

Modest Growth Forecast for the Single-Use Ophthalmic Surgical Device Market

This market will be buoyed by increasing ophthalmic surgical procedures worldwide and fear of cross-contamination, but growth in some segments will be constrained by greater use of micro-surgical techniques.

July 25, 2011:

UK Takes Steps to Ration Cataract Surgery by Changing Visual Acuity Thresholds

Many of the NHS’s PCTs have raised the visual acuity threshold for cataract surgery in an effort to control costs, denying or delaying surgery for thousands of UK residents.

July 25, 2011:

Few FDA Regulatory Approvals for Ophthalmic Devices

The FDA granted few regulatory approvals to ophthalmic devices during the past eight months. Review times increased nearly 60 percent from 2005 to 2010.

July 25, 2011:

2011 FDA Regulatory Approvals for Drugs and Biologics Limited to Generics & New Labeling Thus Far

Generics and labeling changes have dominated FDA regulatory approvals for ophthalmic drugs thus far in 2011, but many await the likely approval of Eylea (VEGF Trap-Eye) later this year.

July 25, 2011:

July 2011 News Briefs

This month's news includes the latest from Transcend Medical, SARcode Bioscience, Ivantis, MicroLabs and Bausch & Lomb.

Social media